Kymab Racing for a U.S. IPO Listing in 3rd Quarter of 2020.

Top Quote Based in Cambridgeshire, Kymab is discovering and developing human monoclonal antibody therapeutics with an initial focus on malaria and HIV. End Quote
  • (1888PressRelease) April 06, 2020 - Led by CEO Simon Sturge, the pharmaceutical company has raised over £200m over seven funding rounds. Investors include LifeArc, Malin Corporation and Wellcome Trust, along with Woodford Investment Management. In 2017 Kymab received a $9m grant from the Bill and Melinda Gates Foundation to accelerate the development of novel vaccines.

    Back in May 2019 it was announced that the Kymab team were considering an IPO on Nasdaq, following the submission of a ‘confidential draft registration statement’. They subsequently made a post stating that “the initial public offering is expected to commence in 2020 after the SEC completes its review process, subject to market and other conditions.”

    The whole World is working towards Vaccines / Treatments for this Virus and while we may not be the first, we are also working with the same drugs that have been available for many years. We will be one of the many companies that will be in great demand once we see a breakthrough in a specific treatment and dosage as well as “cocktail most used with the greatest success rate”, Said Robin Tellurue.

  • FB Icon Twitter Icon In-Icon
Contact Information